AXIM Biotechnologies (OTCMKTS:AXIM – Get Rating) is one of 367 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare AXIM Biotechnologies to related businesses based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Valuation and Earnings
This table compares AXIM Biotechnologies and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AXIM Biotechnologies | N/A | N/A | -3.55 |
| AXIM Biotechnologies Competitors | $143.80 million | -$14.25 million | 86.28 |
AXIM Biotechnologies’ competitors have higher revenue, but lower earnings than AXIM Biotechnologies. AXIM Biotechnologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AXIM Biotechnologies | 0 | 0 | 0 | 0 | N/A |
| AXIM Biotechnologies Competitors | 229 | 1391 | 4113 | 52 | 2.69 |
As a group, “Biotechnology” companies have a potential upside of 79.37%. Given AXIM Biotechnologies’ competitors higher probable upside, analysts plainly believe AXIM Biotechnologies has less favorable growth aspects than its competitors.
Profitability
This table compares AXIM Biotechnologies and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AXIM Biotechnologies | N/A | N/A | N/A |
| AXIM Biotechnologies Competitors | -341.38% | -69.23% | -14.68% |
Institutional & Insider Ownership
28.7% of shares of all “Biotechnology” companies are held by institutional investors. 24.6% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
AXIM Biotechnologies competitors beat AXIM Biotechnologies on 5 of the 8 factors compared.
About AXIM Biotechnologies
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
Receive News & Ratings for AXIM Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AXIM Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
